Xeris Biopharma Holdings, Inc. announced a CEO succession plan effective August 1, 2024, under which Paul R. Edick will be retiring from as CEO of the company after more than seven years with the Company. Pursuant to the Company's succession plan, the Board has appointed, John P. Shannon, Xeris' President and Chief Operating Officer, as the new CEO. Mr. Shannon has been a key member of the company executive leadership team since 2017.

Mr. Edick will serve in a senior advisory role to Xeris through February 1, 2026. Mr. Shannon has over 40 years of experience in the pharmaceutical and healthcare industry with a diverse background in sales, U.S. and global marketing, operations and manufacturing, strategic planning, and business development. Before joining Xeris, Mr. Shannon served as CEO and Director for Catheter Connections, Inc. through its acquisition by Merit Medical.

Prior to that, he served as Chief Commercial Officer for Durata Therapeutics, and held several roles at Baxter Healthcare, including Vice President and General Manager of U.S. BioScience and General Manager, Global Hemophilia and Global Commercial Excellence. Mr. Shannon received a B.S. degree in biology with an emphasis in microbiology from Western Illinois University.